文章预览
来源： 严选IVD原料 瑞士巴塞尔与美国Vacaville | 2024年10月 作为全球最大的医疗健康开发与生产组织之一，龙沙 (Lonza) 宣布已成功完成对罗氏位于美国加利福尼亚州Vacaville的基因泰克大规模生物制品生产基地的收购。收购价格为12亿美元。 以下为英文版新闻原文： The Vacaville facility significantly extends Lonza’s capacity for mammalian manufacturing in the US, the world’s largest pharmaceutical market. It creates a significant West Coast commercial manufacturing presence close to San Francisco’s pharma and biotech hub, complementing Lonza’s existing East Coast manufacturing site in Portsmouth, New Hampshire, as well as its international network across Europe and Asia Pacific. With a total bioreactor capacity of around 330,000 liters, the Vacaville site is one of the largest biologics manufacturing facilities in the world. This acquisition significantly extends manufacturing capacity for late
………………………………
